Eligible studies evaluated subcutaneous tirzepatide at 5 mg, 10 mg, 15 mg, or a participant-specific MTD, defined as dose escalation to either 10 mg or 15 mg based on tolerability, or semaglutide at 2.4 mg or its own MTD (escalated to 1.7 mg or 2.4 mg based on tolerability)
More importantly, we found that the causal effect of ISI on MASLD was independent of BMI, which means the effects of GLP-1R-based agonists on MASLD were partly independent of their weight-loss effect
I was missing some data here and there, was not working out for me
13.5 Regular Medical Follow-Up and Lab Monitoring Routine evaluations ensure therapeutic efficacy and safety
What to avoid while taking berberine
Lower Urinary Tract Symptoms in Obesity Based on recent data released from the CDC: the prevalence of obesity increased from 30.5 to 42.4% from 1999 to 2000 through 20172018, and the prevalence of severe obesity increased from 4.7 to 9.2%